The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...
One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...
ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.
A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...
The study found that about one-third of hospitalized ALS patients experienced difficulty swallowing (dysphagia), and these patients had longer hospital stays, higher healthcare costs, and a greater ...
Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
Add Yahoo as a preferred source to see more of our stories on Google. Long-term air pollution exposure may raise ALS risk and speed disease progression, according to a large Swedish study. (CREDIT: AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results